Blood-Based Alzheimer's and Neurodegeneration Test Developers

Commercial sector

Blood-Based Alzheimer's and Neurodegeneration Test Developers

Companies developing or offering blood tests specifically for Alzheimer's disease and related dementias, measuring analytes such as p-tau217, p-tau181, amyloid-beta 42/40 ratio, NfL, or GFAP for cognitive impairment screening, patient selection for disease-modifying therapies, or treatment monitoring. Includes LDT providers, IVD kit developers, and clinical laboratory services with validated AD blood panels.

Companies18
Commercial products143
Technology classes7
Countries9
Patents635

Profiled companies

Products
  • Roche logo
    Roche
    Switzerland58
  • ALZpath logo
    ALZpath
    United States3
  • Beckman Coulter logo
    Beckman Coulter
    United States24
  • Diazyme Laboratories logo
    Diazyme Laboratories
    United States12
  • Cx Precision Medicine logo
    Cx Precision Medicine
    United States3
  • IBL International logo
    IBL International
    Germany17

+ 12 more

← Back to what’s inside this report